We serve Chemical Name:3-Amino-3-(4-methoxyphenyl)-1-propanol CAS:68208-24-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-Amino-3-(4-methoxyphenyl)-1-propanol
CAS.NO:68208-24-2
Synonyms:3-Amino-3-(4-methoxy-phenyl)-propan-1-ol;3-Amino-3-(4-methoxyphenyl)-1-propanol;Benzenepropanol, γ-amino-4-methoxy-;MFCD01863268;3-amino-3-(4-methoxyphenyl)propan-1-ol
Molecular Formula:C10H15NO2
Molecular Weight:181.232
HS Code:2922509090
Physical and Chemical Properties:
Melting point:82-86ºC
Boiling point:334.2±32.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.546
PSA:55.48000
Exact Mass:181.110275
LogP:0.51
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-Amino-3-(4-methoxy-phenyl)-propan-1-ol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-amino-3-(4-methoxyphenyl)propan-1-ol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-amino-3-(4-methoxyphenyl)propan-1-ol Use and application,3-Amino-3-(4-methoxy-phenyl)-propan-1-ol technical grade,usp/ep/jp grade.
Related News: Fate Therapeutics has exclusively licensed from MSK foundational intellectual property covering the production and composition of iPSC-derived T cells. 3-Amino-3-(4-methoxyphenyl)-1-propanol manufacturer Fate Therapeutics has exclusively licensed from MSK foundational intellectual property covering the production and composition of iPSC-derived T cells. 3-Amino-3-(4-methoxyphenyl)-1-propanol supplier CMO services mainly involve four stages: pre-clinical research, clinical trials, sales of patented drugs after listing, and sales of original drug products after patents expire. Its advantages are: lower cost, guaranteed quality, good capacity flexibility, and favorable process Promotion. 3-Amino-3-(4-methoxyphenyl)-1-propanol vendor At Day 35 following administration, a bone marrow assessment showed that FT819 persisted and continued to demonstrate tumor clearance, whereas primary CAR T cells, while persisting, were not able to control tumor growth. 3-Amino-3-(4-methoxyphenyl)-1-propanol factory This is how an API becomes a medicine.
